Skip to main content
Drug Profiles/Updates, Cholangiocarcinoma
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Loretta Fala, Medical Writer
Loretta Fala, Medical Writer
Drug Profiles/Updates, FDA Oncology Update
December 19, 2019 - FDA News & Updates
Hepatocellular Carcinoma, Lymphoma, Drug Profiles/Updates, FDA Oncology Update
November 18, 2019 — Oncology News & Updates
FDA Updates, Gastrointestinal Cancers, Drug Profiles/Updates
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
Online Only
FDA Updates, Prostate Cancer, Drug Profiles/Updates
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala, Medical Writer
FDA Updates, Leukemia, Drug Profiles/Updates
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
Online Only
Breast Cancer, FDA Updates, Drug Profiles/Updates
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates, Drug Profiles/Updates
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
Online Only
FDA Updates, Drug Profiles/Updates
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh, Medical Writer
Leukemia, Drug Profiles/Updates, FDA Oncology Update
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Page 1 of 4
Results 1 - 10 of 40